Physician profile
John Daula
NPI 1225359789
$4,778.23
in general payments reported to CMS, 2019-2025
23 companies · $2,372 in 2025
The $2,372 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $439 · 2024: $1,967 · 2025: $2,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,774 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,774.44 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $549.64 | 2023-2025 | Spravato |
| Abbvie INC. | $446.23 | 2024-2025 | |
| Lundbeck LLC | $433.04 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $431.49 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $387.34 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $335.48 | 2023-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $333.49 | 2023-2025 | Trintellix |
| Almatica Pharma LLC | $304.09 | 2023-2025 | Loreev Xr |
| Alkermes, INC. | $297.76 | 2024-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $257.16 | 2023-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $250.95 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.48 | 2023-2025 | Caplyta |
| Bausch Health US, LLC | $113.73 | 2023-2024 | Aplenzin |
| Janssen Scientific Affairs, LLC | $73.93 | 2025 | Spravato |
| Tris Pharma INC | $65.23 | 2024 | Dyanavel Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62.19 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $58.47 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $54.00 | 2024-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $34.37 | 2025 | Jornay Pm |
| Tempus Ai, INC | $27.95 | 2024 | |
| Ironshore Pharmaceuticals INC. | $23.46 | 2024 | |
| Noven Therapeutics, LLC | $15.42 | 2024 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $13.33 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Daula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.